INFO:

VANCOUVER — At the Association for Research in Vision and Ophthalmology meeting, Bart Leroy, MD, PhD, discusses retrospective reviews of patients treated with Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics) that found a consistent improvement in visual function lasting up to at least 4 years.